184 related articles for article (PubMed ID: 12113029)
41. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
[TBL] [Abstract][Full Text] [Related]
42. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
43. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
44. The role of new agents in the treatment of colorectal cancer.
Folprecht G; Köhne CH
Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
[TBL] [Abstract][Full Text] [Related]
45. [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Jerusalem G; Bours V; Fillet G
Rev Med Liege; 1998 Jun; 53(6):318-21. PubMed ID: 9713208
[TBL] [Abstract][Full Text] [Related]
46. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Folprecht G; Köhne CH; Lutz MP
Cancer Treat Res; 2007; 134():425-40. PubMed ID: 17633071
[No Abstract] [Full Text] [Related]
47. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
48. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Kopetz S; Morris VK; Parikh N; Overman MJ; Jiang ZQ; Maru D; Elvin P; Gallick G
BMC Cancer; 2014 Sep; 14():660. PubMed ID: 25208577
[TBL] [Abstract][Full Text] [Related]
49. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
Beaven AW; Goldberg RM
Oncology (Williston Park); 2006 Apr; 20(5):461-9; discussion 469-70, 473-5. PubMed ID: 16739745
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of oxaliplatin in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):9-14. PubMed ID: 11204666
[TBL] [Abstract][Full Text] [Related]
52. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
53. First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
Gill S; Goldberg RM
Drugs; 2004; 64(1):27-44. PubMed ID: 14723557
[TBL] [Abstract][Full Text] [Related]
54. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Yu X; Li Z; Yu J; Chan MT; Wu WK
Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
[TBL] [Abstract][Full Text] [Related]
55. [Polymorphism in colorectal cancer].
Hazama S; Oka M; Hinoda Y
Nihon Rinsho; 2003 Sep; 61 Suppl 7():42-6. PubMed ID: 14574853
[No Abstract] [Full Text] [Related]
56. [Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].
Honecker F; Wedding U; Kolb G; Bokemeyer C
Onkologie; 2001 Feb; 24(1):87-94. PubMed ID: 11441288
[TBL] [Abstract][Full Text] [Related]
57. [New perspectives in predicting response to chemotherapy in colorectal cancer].
Sempere L; Jover R
Gastroenterol Hepatol; 2008 Nov; 31(9):580-6. PubMed ID: 19091247
[TBL] [Abstract][Full Text] [Related]
58. New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.
Egreteau J; Boucher E; de Guibert S; Jacquelinet C; Meunier B; Boudjema K; Raoul JL
Int J Gastrointest Cancer; 2005; 35(1):69-76. PubMed ID: 15722576
[TBL] [Abstract][Full Text] [Related]
59. [Molecular biology in clinical cancer research: the example of digestive cancers].
Lièvre A; Laurent-Puig P
Rev Epidemiol Sante Publique; 2005 Jun; 53(3):267-82. PubMed ID: 16227914
[TBL] [Abstract][Full Text] [Related]
60. Role of genomic markers in colorectal cancer treatment.
Allen WL; Johnston PG
J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
